Histone methyltransferase that specifically monomethylates Lys-4 of histone H3. H3 Lys-4 methylation represents a specific tag for epigenetic transcriptional activation. Plays a central role in the transcriptional activation of genes such as collagenase or insulin. Recruited by IPF1/PDX-1 to the insulin promoter, leading to activate transcription. Has also methyltransferase activity toward non-histone proteins such as p53/TP53, TAF10, and possibly TAF7 by recognizing and binding the [KR]-[STA]-K in substrate proteins. Monomethylates Lys-189 of TAF10, leading to increase the affinity of TAF10 for RNA polymerase II. Monomethylates Lys-372 of p53/TP53, stabilizing p53/TP53 and increasing p53/TP53-mediated transcriptional activation.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human SETD7 (AA: 107-366) expressed in E. Coli.
The protein encoded by this gene belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein forms a heterodimer with BCL2, and functions as an apoptotic activator. The association and the ratio of BAX to BCL2 also determines survival or death of a cell following an apoptotic stimulus. This protein is reported to interact with, and increase the opening of, the mitochondrial voltage-dependent anion channel (VDAC), which leads to the loss in membrane potential and the release of cytochrome c. The expression of this gene is regulated by the tumor suppressor P53 and has been shown to be involved in P53-mediated apoptosis. Multiple alternatively spliced transcript variants, which encode different isoforms, have been reported for this gene. [provided by RefSeq, Dec 2019]
Product Type:
Antibodies Primary
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human BAX (AA:(13-160)) expressed in E. Coli.
This gene encodes a member of the p53 family of transcription factors. The functional domains of p53 family proteins include an N-terminal transactivation domain, a central DNA-binding domain and an oligomerization domain. Alternative splicing of this gene and the use of alternative promoters results in multiple transcript variants encoding different isoforms that vary in their functional properties. These isoforms function during skin development and maintenance, adult stem/progenitor cell regulation, heart development and premature aging. Some isoforms have been found to protect the germline by eliminating oocytes or testicular germ cells that have suffered DNA damage. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8.
Product Type:
Antibodies Primary
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human TP63 (AA: 5-17) expressed in E. Coli.
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Product Type:
Antibodies Primary
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human CDKN2A/P16 (AA: 1-156) expressed in E. Coli.
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Product Type:
Antibodies Primary
Storage Temp:
4°C -20°C for long term storage
Immunogen:
Purified recombinant fragment of human CDKN2A (AA: 1-156) expressed in E. Coli.
PAb 122 binds to the C-terminus (aa370-378) of both wild type and mutated p53. When microinjected into nuclei, PAb 122 blocked re-entry into the S-phase of the cell cycle. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. p53 Localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution.
FR5A10 reacts with CD21, a 140 kDa cell surface molecule which acts as a receptor for EBV, for human complement factor C3d (CR2) and for IFN-alpha. It is a glycoprotein, made up of multiple (n=15) Short Consensus Repeats (S.C.R.) sequences. FR5A10 has been assigned to (S.C.R.) sequences. FR5A10 has been assigned to S.C.R. numbers 5-8. FR5A10 is highly specific to CR2 and shows no cross-reaction with CR1. CD21 is expressed strongly on mature B-cells, follicular dendritic cells and weakly on immature thymocytes and T-lymphocytes. In B-cell ontogeny, CD21 appears after the preB-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CD21 expression is also gradually lost after stimulation of B-cells in vitro.
Antibody Isotype:
IgG1-K
Monosan Range:
MONOSAN
Clone:
FR5A10
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Schlossman SF et al. Leukocyte Typing?V Oxford?University Press:?342-352 (1995)
References 2:
Aubry JP et al. Leukocyte Typing V, p535-536, Oxford University Press, Oxford, (1995)
EBS-I-100 reacts with C. difficile Toxin A, but not with V. cholerae subunit a, V. cholerae toxin, Pseudomonas aeruginosa exotoxin A, H-LT, P-LT. C. difficile is a major nosocomial pathogen that causes antibiotic-associated colitis and mediates inflammatory diarrhea by releasing two large protein enterotoxins (toxin A and toxin B) that are able to disrupt intestinal epithelial cells via their transferase activity and ability to monoglucosylate members of the Rho family. C. difficile toxin A is a toxin that is composed of 39 repeats that are responsible for binding to intestinal epithelial cell surface carbohydrates. C. difficile toxin A causes significant apoptosis of colonocytes which contributes to the formation of ulcers and pseudo-membranes in a pathway that involves p38-dependent activation of p53 and induction of p21, leading to cytochrome c release and caspase-3 activation through Bak activation.
Antibody Isotype:
IgG3-K
Monosan Range:
MONOSAN
Clone:
EBS-I-100
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Kim H, et al, Gastroenterology 129: 1875-1888 (2005)
References 2:
Carter JP, et al, Gut Microbes. 1(1): 5864 (2010)
Bp53-12 reacts with an N-terminal epitope (aa 16-25) of both wild-type and mutated p53. This epitope is revealed in tissue sections only after formalin fixation. Mutation and/or allelic loss of p53 is one of the causes of a variety of mesenchymal and epithelial tumors. p53 Localizes in the nucleus, but is detectable at the plasma membrane during mitosis and when certain mutations modulate cytoplasmic/nuclear distribution.
Antibody Isotype:
IgG2a-A
Monosan Range:
MONOSAN
Clone:
Bp53-12
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Bártek J. et al, J Pathol. 169(1):27-34 (1993)
References 2:
Vogelstein and Kinzler, Cell 70: 523-526, (1992)
References 3:
Hollstein et al, Science 253: 49-53: (1991)
References 4:
Lane, D.P, Nature 358: 15-16: (1992)
References 5:
Donehower et al, Biochemic. Biophys. Acta 1155: 181-182, (1993)
WA-1 reacts with human and other mammalian p21, a tumor suppressor protein, belonging to the CDI family. The intracellular protein p21 is a 21 kDa protein, also known as wild-type p53-activated fragment 1 (WAF1). It is an inhibitor of cyclin-dependent kinases (Cdks) and of proliferating-cell nuclear antigen (PCNA). It is induced by wild type p53, but not by mutated p53, by mezerein (anti-leukemic compound) and by interferon-ß. Normal cells generally display a rather intense nuclear p21 expression. Loss of p21 expression has been reported in many carcinomas (gastric carcinoma, non-small cell lung carcinoma and thyroid carcinoma).
Antibody Isotype:
IgG1
Monosan Range:
MONOSAN
Clone:
WA-1
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Kovaric, J. et al, Int. J. Oncol. 9(suppl.), 835 (1996)
This antibody reacts with the C-terminus of Nucleophosmin (B23). NPM1 (Nucleophosmin 1, B23, nutramin, NO38) is a ubiquitously expressed phosphoprotein involved in ribosome assembly/transport, cytoplasmic/nuclear trafficking, regulation of DNA polymerase alpha activity, centrosome duplication, and regulation of p53. NPM1 continuously shuttles between the nucleus, cytoplasm, nucleolus and chaperoning core histones from the nucleus to the cytoplasm.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Concentrate
Storage Temp:
2-8 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
GMDN Code:
57047
UKCA Status:
UKCA
CE-IVD Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The gene encoding WAF1, also termed p21, is transcriptionally regulated by the suppressor protein, p53. Overexpression of WAF1 is growth suppressive, possibly by inhibiting the activity of cyclin/CDK complexes. One consequence of WAF1 binding to cyclin/CDK is the inhibition of Rb protein phosphorylation. Induction of WAF1 expression requires wild type p53 activity in cells undergoing p53 dependent G1 arrest or apoptosis. Mutation of the p53 gene is a common event in human cancer and results in the failure to produce WAF1. The effect of this may lead to uncontrolled cell proliferation.
Antibody Isotype:
IgG1
Monosan Range:
MONXtra
Clone:
4D10
Concentration:
n/a
Storage buffer:
Tissue culture supernatant with 15 mM sodium azide
Storage:
2-8°C
References 1:
Göhring UJ et al. Journal of Clinical Pathology. 54: 866870 (2001)
References 2:
Schwerer MJ et al. Journal of Clinical Pathology. 54: 871876 (2001)
References 3:
Tweddle DA et al. American Journal of Pathology. 158 (6): 20672077 (2001)
References 4:
Garcia JF et al. Histopathology. 30: 120125 (1997)
This monoclonal antibody recognizes both wild type and mutant forms of human p53 protein under denaturing and non-denaturing conditions. The epitope recognized by clone DO-7 can be destroyed by prolonged fixation in buffered formalin. The heat induced epitope retrieval technique may improve staining in some cases.
Antibody Isotype:
IgG2b
Monosan Range:
MONXtra
Clone:
DO-7
Concentration:
Greater than or equal to 22 mg/L
Storage buffer:
Tissue culture supernatant with sodium azide
Storage:
2-8°C
References 1:
Tiniakos DG et al. Cytopathology. 1996; 7(3): 178186
References 2:
Yoshida T et al. Journal of Pathology. 2003; 199(2):166175
References 3:
Burns ASYW et al. British Journal of Cancer. 2002; 86(7):11171123
References 4:
Tweddle DA et al. American Journal of Pathology. 2001; 158(6): 20672077
References 5:
Fernando SS et al. International Journal of Surgical Pathology. 2000; 8(3):213222
The gene coding for p53 oncoprotein is located on chromosome 17p. Allele loss at this chromosome site has frequently been seen in many tumours including lung, colon, breast and brain. Expression of p53 oncoprotein was not detected in normal mucosa, whereas mutation results in a detectable expression of the p53 protein. It is therefore suggested that immunocytochemical detection of p53 protein is an indication for malignancy. Positive control: Breast carcinoma.
BXP-53 reacts with an internal epitope of bcrp, a 70 kD transmembrane half-transporter which is involved in Multidrug resistance. BXP-53 also reacts with the human BCRP molecule.
The antibody neutralizes mouse interleukin 6 (IL-6). It does not cross-react with LPS (the component of the bacterial cell wall which is considered responsible for the toxicity of gram-negative bacteria) and TNFalpha nor does it block human or rat IL-6 in proliferation assays using the KD83 cell line. MP5-32C11 inhibits mouse IL-6-induced proliferation of the NFS60 myelomonocytic cell line and KD83 plasmacytoma. IL-6 is a pluripotent 20-22 kDa cytokine which plays a role in the pathophysiology of severe infection and regulates the immune response, acute phase reaction and haematopoiesis. IL-6 plays a critical role in Bcell differentiation to plasma cells and is a potent growth factor for plasmacytoma and myeloma. Continuous IL-6 gene expression makes an essential contribution to a multistep oncogenesis of plasma cell neoplasia. IL-6 is a very useful culture supplement for the generation of a high number of antibodyproducing hybridomas.
SV40, Simian Virus 40 is a polyomavirus that is found in both monkeys and humans. Like other polyomaviruses, SV40 is a DNA virus that has the potential to cause tumors. SV40 is believed to suppress the transcriptional properties of tumor-suppressing p53 in humans through the SV40 large T-antigen and SV40 small T-antigen. It is generally assumed that large T-antigen is the major protein involved in neoplastic processes and the large T-antigen predominantly exerts its effect through deregulation of tumor suppressor p53, which is responsible for initiating regulated cell death (apoptosis), or cell cycle arrest when a cell is damaged. A mutated p53 gene may contribute to uncontrolled cellular proliferation, leading to a tumor.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
MRQ-4
Concentration:
n/a
Storage buffer:
Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Storage:
2-8°C
References 1:
Gurney, E.G., et al. J Virl. 34:752-763 (1980)
References 2:
Huang, H., Reis,R. et al. Brain Pathol., 9:33-42 (1999)
References 3:
Arrington, A.S., et al. Molecular and Clinical Perspectives; 461-489 (2001)
The antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild type p53.1 Positive nuclear staining with this antibody has been shown to be a factor in breast carcinoma, lung carcinoma, colorectal carcinoma, urothelial carcinoma, and ependymoma.2-8 Anti-p53 positivity has also been used to differentiate uterine serous carcinoma from endometrioid carcinoma, as well as a marker for intratubular germ cell neoplasia.
Antibody Isotype:
IgG2b-k
Monosan Range:
MONOSAN
Clone:
DO7
Concentration:
n/a
Storage buffer:
Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Storage:
2-8°C
References 1:
Mauri FA et al. Int J Oncol 1999 Dec;15(6):1137-47
References 2:
Caffo O et al. Clin Cancer Res 1996 Sep;2(9):1591-9
References 3:
Bebenek M et al. Anticancer Res 1998 Jan-Feb;18(1B):619-23
References 4:
Midulla C et al. Anticancer Res 1999 Sep-Oct;19(5B):4033-7
References 5:
Moore BE et al. App.IHC and Mol. Morphol. 2001;9(3): 203 206
p21 is one of the inhibitors of the phosphorylation of the cyclin-cdk complex. p21, which is an inhibitor of G1 cdks, suppresses the cell cycle and inhibits DNA synthesis. Although p21 is induced by p53 and inhibits cdk (cyclin-dependent kinase) activity, there was virtually no correlation between the expression of p21 and that of p53; this finding was consistent with two reports, though another reported an inverse correlation between the expression of p21 and that of p53. p53independent expression of p21 might account for the discrepancy between the expression of p53 and that of p21. It is expressed in normal human tissue and a wide array of tumors.
Antibody Isotype:
IgG1-k
Monosan Range:
MONOSAN
Clone:
DCS-60.2
Concentration:
n/a
Storage buffer:
Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Breast, Prostate, Prostate carcinoma or lung or bladder squamous cell carcinoma
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
TP63/11
Concentration:
n/a
Format:
Concentrate
Storage buffer:
Bioreactor Concentrate with 0.05% Azide
Storage:
2-8°C
References 1:
Yang A, et al. Mol Cell 1998;2:305-16
References 2:
Signoretti S, et al Am J Pathol 2000;157:1769-75
References 3:
Yang A, et al. Nature 1999;398:714-18
References 4:
Barbareschi M. et al. Am J Surg Pathol 2001 Aug;25(8);1054-60
References 5:
Werling RW, et al. Am J Surg Pathol 2003 Jan;27(1):82-90
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
